Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-Effectiveness Analyses for Sequential Multiple Assignment Randomized Trials.

Statistics in medicine·2026
Same author

An approach to nonparametric inference on the causal dose-response function.

Journal of causal inference·2026
Same author

A megastudy of behavioral interventions to promote frequent HIV testing among adults at high risk of HIV infection in Kenya and Uganda: study protocol for a randomized controlled trial.

Trials·2026
Same author

Sequential invitations to FOBT screening and colorectal cancer incidence.

Scientific reports·2026
Same author

Powering RCTs for Marginal Effects With GLMs Using Prognostic Score Adjustment.

Statistics in medicine·2026
Same author

Machine learning to optimize precision in the analysis of randomized trials: A journey in pre-specified, yet data-adaptive learning.

Clinical trials (London, England)·2026

Related Experiment Video

Updated: Jul 15, 2026

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

Individualized treatment rules: generating candidate clinical trials.

Maya L Petersen1, Steven G Deeks, Mark J van der Laan

  • 1Division of Biostatistics, University of California, School of Public Health, Earl Warren Hall #7360, Berkeley, CA 94720-7360, U.S.A. mayaliv@berkeley.edu

Statistics in Medicine
|April 24, 2007
PubMed
Summary

This study explores statically optimal treatment rules, crucial for personalized medicine. History-adjusted marginal structural models (HA-MSM) can identify these rules, ensuring treatment plans are optimal regardless of past treatment assignment.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Related Experiment Videos

Last Updated: Jul 15, 2026

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Area of Science:

  • Biostatistics
  • Clinical Medicine
  • Epidemiology

Background:

  • Individualized treatment rules are vital for tailoring medical interventions over time.
  • Optimal dynamic treatment regimes aim to maximize patient outcomes.
  • Static treatment rules offer an alternative approach to optimizing care.

Purpose of the Study:

  • To investigate the conditions under which History-Adjusted Marginal Structural Models (HA-MSM) yield statically optimal treatment rules.
  • To ensure treatment rules are independent of past treatment assignment methods.
  • To identify treatment rules suitable for randomized controlled trial evaluation.

Main Methods:

  • Utilizing History-Adjusted Marginal Structural Models (HA-MSM).
  • Analyzing conditions for static optimality of treatment rules.
  • Demonstrating methods with HIV antiretroviral treatment data.

Main Results:

  • HA-MSM-derived rules can be statically optimal if they account for confounding factors in past treatment history.
  • A history-adjusted individualized treatment rule is statically optimal when covariates sufficiently control for treatment history's effect on outcome.
  • The study provides a framework for developing robust, time-dependent treatment strategies.

Conclusions:

  • Statically optimal treatment rules identified by HA-MSM can guide clinical decisions effectively.
  • Ensuring rules are based on covariates that control for confounding is key to their reliability.
  • These methods are applicable to complex treatment scenarios, such as managing HIV resistance.